Semaglutide 7.5mg: where this dose fits in the Wegovy titration schedule

What the clinical evidence tells us about semaglutide's dose-response relationship

The STEP 1 trial, published in the New England Journal of Medicine, followed 1,961 adults with obesity over 68 weeks. Participants receiving semaglutide 2.4mg alongside lifestyle changes lost an average of around 15% of their body weight, a result that shaped semaglutide's UK licensing for weight management. The trial used the same stepped titration now written into Wegovy's prescribing information: a low starting dose, held for several weeks, then gradually increased. That structure isn't incidental. Starting at 0.25mg lets the body adjust to the medicine's effects on gastric emptying and appetite signalling before moving to a dose with meaningful therapeutic effect. Jumping to a higher, unlicensed amount skips that protective logic entirely.

The 7.2mg approval, confirmed by the MHRA in early 2026, was based on separate trial data showing around 20.7% average weight loss over 72 weeks, a result that narrows the gap with tirzepatide at its highest dose. That approval went through the standard regulatory process; the dose is real, licensed, and backed by evidence. A figure of 7.5mg has no equivalent evidence base or UK authorisation. If a seller is advertising semaglutide at 7.5mg as a weight-loss product, the MHRA's guidance on unlicensed and counterfeit weight-loss products is directly relevant, you can report suspect products via the MHRA Yellow Card scheme.

The five licensed steps, and what each one is actually for

Wegovy's titration schedule is worth understanding in plain terms, because it's one of the things prescribers spend real time explaining. The 0.25mg starting dose (described in detail on our semaglutide dosing guide) is purely an adjustment phase. Your system is meeting a GLP-1 receptor agonist for the first time, and the goal for those first four weeks is tolerance, not weight loss. Moving to 0.5mg is the first step toward meaningful effect, and by the time a patient reaches 1.7mg or 2.4mg, most of the gastrointestinal adjustment has already happened.

The 2.4mg maintenance dose is where the STEP 1 trial ran its 68-week phase. The newly approved 7.2mg dose extends that ceiling further, and the dedicated single-dose pen approved in April 2026 (with its auto-dosing mechanism and built-in covered needle) makes that higher dose more straightforward to administer. But reaching it still involves the same patient titration from 0.25mg upward; the starting point doesn't change. For a fuller picture of all the available Wegovy strengths, the Wegovy doses page sets out the full schedule alongside what each stage is designed to achieve.

One practical note: many patients find the early weeks of dose adjustment easier when they have a prescriber they can actually reach. Side effects like nausea often peak in the day or two after an injection, then settle before the next weekly dose. Knowing that pattern in advance (rather than discovering it on a Wednesday evening with no one to call) makes a noticeable difference.

Why a dose that doesn't exist in the licensed schedule is a safety concern

The MHRA has been clear, and increasingly active, on the counterfeit market for weight-loss injectables. Large seizures of fake pens have been made across the UK, including the first illicit manufacturing site for counterfeit tirzepatide pens, raided in 2025. Some fake products have been found to contain insulin rather than the labelled medicine, a risk that could cause serious harm in someone who has not been assessed for diabetes. Semaglutide 7.5mg, as an unlicensed strength, sits outside the framework of clinical evidence, regulatory oversight, and supply-chain verification that legitimate treatment depends on.

If you're weighing up private treatment options, the right starting point is verifying any pharmacy on the GPhC register before anything else. A GPhC-registered pharmacy can only dispense Wegovy against a valid prescription issued following a clinical assessment, that's not a formality, it's the mechanism that keeps patients safe. You can read more about the full picture of semaglutide for weight management on the Wegovy overview page, or explore weight-loss treatment options more broadly if you're still in the research stage.

For anyone specifically researching cost alongside clinical safety, our guide to getting Wegovy in the UK covers what to look for in a provider and what genuine private treatment includes. The short version: a legitimate service will always begin with a clinical consultation, not a basket.

Starting semaglutide through a regulated service

At nume, every consultation is personally read by a GPhC-registered Independent Prescriber, a real clinician reviews your answers, the same day. There's no algorithm making the call. If you're clinically suitable, treatment is dispatched the same day you order (provided you order before noon on a weekday), and arrives free the next working day in plain, unbranded packaging via DPD. The price covers consultation, prescription, delivery, and seven-day aftercare, nothing added later.

If the primary keyword that brought you here was semaglutide 7.5mg, the honest answer is that this strength doesn't exist in the licensed UK schedule. The licensed pathway, properly supervised, is what produces the results the clinical trials actually measured. If you'd like to find out whether Wegovy is right for you, start your free consultation, our prescribers are there to answer the questions a search engine can't.